Strongbridge Biopharma plc - Ordinary Shares (SBBP) News
Filter SBBP News Items
SBBP News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
SBBP News Highlights
- For SBBP, its 30 day story count is now at 8.
- Over the past 27 days, the trend for SBBP's stories per day has been choppy and unclear. It has oscillated between 1 and 3.
- The most mentioned tickers in articles about SBBP are ACT, XERS and SC.
Latest SBBP News From Around the Web
Below are the latest news stories about Strongbridge Biopharma plc that investors may wish to consider to help them evaluate SBBP as an investment opportunity.
Strongbridge Biopharma plc Announces Completion of Acquisition by Xeris Pharmaceuticals, Inc.DUBLIN, Ireland and TREVOSE, Pa., Oct. 05, 2021 (GLOBE NEWSWIRE) -- Strongbridge Biopharma plc (NASDAQ: SBBP) (the “Company” or “Strongbridge”) today announced that the High Court of Ireland (the "Court") has approved the previously announced proposed acquisition of Strongbridge by Xeris Pharmaceuticals, Inc. (Nasdaq: XERS) (“Xeris”) by means of a scheme of arrangement (the "Scheme") under Chapter 1 of Part 9 of the Irish Companies Act 2014 (the "Act"). The Court sanction hearing in relation to |
Strongbridge Biopharma plc Announces Court Hearing Date to Approve Proposed Acquisition by Xeris Pharmaceuticals, Inc.DUBLIN, Ireland and TREVOSE, Pa., Sept. 23, 2021 (GLOBE NEWSWIRE) -- Strongbridge Biopharma plc (NASDAQ: SBBP) (the Company or Strongbridge ) today announced that the High Court of Ireland (the Court ) has set the date of the final court hearing to sanction the proposed acquisition of Strongbridge by Xeris Pharmaceuticals, Inc. ( Xeris ) by means of scheme of arrangement (the Scheme ) under Chapter 1 of Part 9 of the Irish Companies Act 2014 (the Act ). |
Xeris Pharmaceuticals Stockholders Approve Acquisition of Strongbridge BiopharmaCHICAGO--(BUSINESS WIRE)--Xeris Pharmaceuticals, Inc. (Nasdaq: XERS) (Xeris) today announced that its stockholders have voted to approve the previously announced proposed acquisition of Strongbridge Biopharma plc (NASDAQ: SBBP) (Strongbridge) by Xeris. At the special meeting of Xeris stockholders held on September 14, 2021, approximately 97% of the shares voted were cast in favor of the acquisition, representing approximately 59% of Xeris total outstanding shares of common stock. Xeris wil |
Strongbridge Biopharma plc Announces Shareholder Approval of Proposed Acquisition by Xeris Pharmaceuticals, Inc.DUBLIN, Ireland and TREVOSE, Pa., Sept. 08, 2021 (GLOBE NEWSWIRE) -- Strongbridge Biopharma plc (NASDAQ: SBBP) (the Company or Strongbridge ) today announced that its shareholders have voted to approve the previously announced proposed acquisition of Strongbridge by Xeris Pharmaceuticals, Inc. (NASDAQ: XERS) ( Xeris ). As described below, at least 99 percent of the votes cast at both a special court-ordered meeting of shareholders (the Court Meeting ) and at an extraordinary general meeting of shareholders (the EGM ) were in favor of the transaction, representing (in each case) approximately 67 percent of the shares outstanding and eligible to be voted at each of the Strongbridge shareholder meetings held on September 8, 2021 in Pennsylvania, United States of America. Upon close of... |
Second Leading Independent Proxy Advisory Firm Glass Lewis Recommends Strongbridge Biopharma plc Shareholders Vote FOR the Transaction With XerisGlass Lewis Joins ISS in Recommending Strongbridge Shareholders Vote FOR Transaction with Xeris |
Second Leading Independent Proxy Advisory Firm Glass Lewis Recommends Strongbridge Biopharma plc Shareholders Vote “FOR” the Transaction With XerisGlass Lewis Joins ISS in Recommending Strongbridge Shareholders Vote “FOR” Transaction with Xeris Strongbridge Urges Shareholders to Vote “FOR” All Transaction-Related Proposals DUBLIN, Ireland and TREVOSE, Pa., Aug. 31, 2021 (GLOBE NEWSWIRE) -- Strongbridge Biopharma plc (Nasdaq: SBBP) (“Strongbridge”) today announced that Glass Lewis & Co. (“Glass Lewis”) has recommended that Strongbridge shareholders vote “FOR” all proposals related to the Company’s transaction with Xeris Pharmaceuticals (Nas |
Xeris Pharmaceuticals Announces Leading Independent Proxy Advisory Firm, ISS, Recommends Xeris Stockholders Vote FOR the Transaction With Strongbridge BiopharmaCHICAGO--(BUSINESS WIRE)--Xeris Pharmaceuticals, Inc. (Nasdaq: XERS) today announced that a leading independent proxy advisory firm Institutional Shareholder Services (ISS) has recommended that Xeris stockholders vote FOR all proposals related to the Companys transaction with Strongbridge Biopharma plc (Nasdaq: SBBP) (Strongbridge). We are pleased that ISS supports our Boards recommendation to vote FOR the acquisition of Strongbridge. In its report, ISS recognizes the valuation, stra |
Leading Independent Proxy Advisory Firm ISS Recommends Strongbridge Biopharma plc Shareholders Vote FOR the Transaction With XerisStrongbridge Urges Shareholders to Vote FOR All Transaction-Related Proposals Strongbridge Urges Shareholders to Vote FOR All Transaction-Related Proposals |
Leading Independent Proxy Advisory Firm ISS Recommends Strongbridge Biopharma plc Shareholders Vote “FOR” the Transaction With XerisStrongbridge Urges Shareholders to Vote “FOR” All Transaction-Related ProposalsDUBLIN, Ireland and TREVOSE, Pa., Aug. 30, 2021 (GLOBE NEWSWIRE) -- Strongbridge Biopharma plc (Nasdaq: SBBP) (“Strongbridge”) today announced that the leading independent proxy advisory firm Institutional Shareholder Services (“ISS”) has recommended that Strongbridge shareholders vote “FOR” the Company’s transaction with Xeris Pharmaceuticals (Nasdaq: XERS) (“Xeris”). In its August 27, 2021 report, ISS recognized the |
INVESTIGATION: Halper Sadeh LLP Investigates SBBP, QTS, GRA, SWN, ONEM, IKNX; Shareholders are Encouraged to Contact the FirmHalper Sadeh LLP, a global investor rights law firm, announces it is investigating the following companies: |